ImaginAb secures supply agreement with Genmab A/S

By staff writers

May 6, 2022 -- ImaginAb has signed a multiyear licensing agreement with Genmab to supply the company with its investigational zirconium-89 (Zr-89)-based PET radiopharmaceutical for use in clinical trials.

Zr-89 crefmirlimab berdoxam is an immuno-PET tracer that binds the CD8 receptor on human T cells and is used for quantitative PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies.

The radiotracer eventually may be used in quantitative imaging of CD8 T cells to determine the immune status of patients and measure the efficacy of immunotherapies, the company said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking